financetom
Business
financetom
/
Business
/
BMW will return to growth in China with new all-electric series, CFO says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BMW will return to growth in China with new all-electric series, CFO says
Sep 6, 2025 2:52 AM

MUNICH (Reuters) -BMW is confident it can return to growth in its largest market China with the all-electric Neue Klasse series, a major overhaul of the company's portfolio that was kick-started this week with the launch of its first model.

"We are more than competitive with this product," Chief Financial Officer Walter Mertl told Reuters. "With increasing availability of the Neue Klasse, we will see growth in China again."

Like its European peers, BMW has suffered setbacks in China due to aggressive local competition and a real estate downturn that has put wealthy Chinese consumers off buying new cars.

In the first half of 2025, China sales at the German luxury carmaker slumped by 15.5%.

"Looking at our future model range, I'm not worried," Mertl said, after BMW took the wraps off its Neue Klasse iX3 electric sport utility vehicle on Friday, which will launch in China by summer 2026.

The launch took place ahead of the 2025 IAA car show in Munich, where local car brands are battling with a growing Chinese presence to remain competitive.

Batteries in the new vehicles were between 40% and 50% cheaper than those in existing models, Mertl said, a key factor in helping the group boost profitability.

With the iX3 50, BMW could achieve margins equal to combustion engine equivalents -- so-called margin parity -- already in 2026, Mertl said.

BMW expects an automotive EBIT margin of 5% to 7% in 2025 and Mertl said the goal was to raise that to 8% to 10% in the future.

The company plans to phase out its old models by the end of the decade with the roll-out of the Neue Klasse series.

Turning to import tariffs in the United States, where BMW has its biggest production plant, Mertl reiterated that the duties would drag BMW's profit margin down by 1.25 percentage points in 2025.

The European Union plans to remove duties on imported U.S. industrial goods in return for a U.S. tariff rate of 15% on European cars - down from the current 27.5% - which automakers hope will apply retroactively from August 1.

(Writing by Rachel More; Editing by Christoph Steitz: Editing by Sharon Singleton)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cbl & Associates Properties Insider Sold Shares Worth $370,501, According to a Recent SEC Filing
Cbl & Associates Properties Insider Sold Shares Worth $370,501, According to a Recent SEC Filing
Mar 11, 2024
02:22 PM EDT, 03/11/2024 (MT Newswires) -- Stephen D Lebovitz, Director, CEO, on March 07, 2024, sold 15,893 shares in Cbl & Associates Properties ( CBL ) for $370,501. Following the Form 4 filing with the SEC, Lebovitz has control over a total of 404,018 shares of the company, with 403,696 shares held directly and 322 controlled indirectly. SEC Filing:...
Boeing Stock Is Losing Altitude Monday: What's Going On?
Boeing Stock Is Losing Altitude Monday: What's Going On?
Mar 11, 2024
Boeing Co ( BA ) shares are trading lower Monday following reports the Justice Department is opening an investigation into the Alaska Airlines door blowout event. What To Know: According to a Bloomberg report, the U.S. Justice Department has convened a grand jury as part of a criminal investigation into the Alaska Airlines flight incident in which a door plug...
Usana Health Sciences Insider Sold Shares Worth $257,022, According to a Recent SEC Filing
Usana Health Sciences Insider Sold Shares Worth $257,022, According to a Recent SEC Filing
Mar 11, 2024
02:32 PM EDT, 03/11/2024 (MT Newswires) -- Walter Noot, COO, on March 08, 2024, sold 5,240 shares in Usana Health Sciences ( USNA ) for $257,022. SEC Filing: https://www.sec.gov/Archives/edgar/data/896264/000089626424000113/xslF345X03/wk-form4_1710181361.xml Price: 49.05, Change: +0.47, Percent Change: +0.97 ...
Moderna, Merck to Begin Phase 2/3 Study of V940 Plus Pembrolizumab in Skin Cancer
Moderna, Merck to Begin Phase 2/3 Study of V940 Plus Pembrolizumab in Skin Cancer
Mar 11, 2024
02:26 PM EDT, 03/11/2024 (MT Newswires) -- Moderna ( MRNA ) and Merck ( MRK ) will start a phase 2/3 study of cancer vaccine V940, or mRNA-4157, plus pembrolizumab in patients with cutaneous squamous cell carcinoma, a form of skin cancer, according to a government trial website. The study is expected to begin on April 18, according to ClinicalTrials.gov....
Copyright 2023-2026 - www.financetom.com All Rights Reserved